Free · no account · quoted from the filing

What changed in COR's 10-Q

Source: 10-Q filed 2026-05-06 · compared against 10-Q 2026-02-04. Every passage below is quoted verbatim from the filing itself.

Acquisition

This filing
On February 2, 2026, we acquired the majority of the outstanding equity interests that we did not previously own in OneOncology

Balance Sheet

This filing
Assets held for sale $ 3,849,666

Revenue Growth

This filing
Revenue increased by $2.9 billion, or 3.8%

Capital Expenditures

This filing
total capital expenditures $ 165,618
What it means — the analyst reading

The passages above are the company's own words. The plain-English reading of them — what changed, why it matters, and the direction of travel, plus 1 further change without a quotable passage — is part of the Filing Change Monitor.

See the Filing Change Monitor →

Compared from narrative excerpts (outlook, risks, MD&A) of both filings — quotes are verbatim from the new filing. Not advice. Source: company SEC filings via stockportfolio.pro. Educational, not investment advice.